Angus Liu
Deputy Editor at Fierce Biotech
Deputy Editor at FiercePharma
Biopharma follower @FiercePharma & @FierceBiotech. Medill MSJ 16
Articles
-
1 day ago |
fiercepharma.com | Ayla Ellison |Angus Liu |Gabrielle Masson |Zoey Becker
Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The Top Line," Fierce reporters take you inside the action at ASCO 2025. Zoey Becker shares the story behind Johnson & Johnson’s dramatic “Breathtaking” campaign, staged on the 99th floor of Chicago’s Willis Tower.
-
1 day ago |
fiercepharma.com | Angus Liu
The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. AstraZeneca and Daiichi Sankyo trotted out Enhertu's detailed data in first-line breast cancer. Regeneron signed on a GLP-1/GIP candidate from China's Hansoh Pharma. And more. 1.
-
2 days ago |
fiercepharma.com | Angus Liu
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. It’s more than just existing PD-1/L1 players potentially looking for bispecifics to bolster their positions; whether checkpoint inhibitor wannabes will use these next-generation antibodies to make up for lost PD-1 opportunities—and potentially leapfrog makers of anti-PD-1 drugs—remains an open topic for discussion.
-
3 days ago |
fiercebiotech.com | Angus Liu
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. It’s more than just existing PD-1/L1 players potentially looking for bispecifics to bolster their positions, but whether checkpoint inhibitor wannabes will use these next-generation antibodies to make up for lost PD-1 opportunities—and potentially leapfrog makers of anti-PD-1 drugs—remains an open topic for discussion.
-
4 days ago |
fiercepharma.com | Angus Liu
The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in castration-sensitive disease, although the drug’s benefit in a patient subgroup remains unclear.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 757
- Tweets
- 107
- DMs Open
- No
Was just wondering what Vivek's been up to.
Vivek Ramaswamy set to launch Ohio governor bid on Feb. 24 https://t.co/cXGHsIE7lY
... Yunchan Lim ... Rach 2 ... 😭
RT @FiercePharma: Akeso, Summit's ivonescimab crushes Merck's Keytruda in China study, signaling potential new standard of care in lung can…
